A Clinical Research on Disease Progression and Intervention of Chronic HepatitisB
NCT ID: NCT05057065
Last Updated: 2021-09-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
10000 participants
OBSERVATIONAL
2021-09-15
2023-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Follow-up Study of Chronic Hepatitis B Patients With Liver Cirrhosis Receiving Anti-HBV Therapy
NCT01957618
The Effect of Metabolic Syndrome on Antiviral Response in People With Chronic Hepatitis B
NCT05705141
Population-wide Research for HBV-related Liver Diseases in Maoming City
NCT06184347
Observational Study on Patients With Chronic Hepatitis B
NCT02167503
Dynamic Changes of Serum HBV RNA in Chronic Hepatitis B Patients
NCT05991531
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To evaluate the impact of metabolic disease on the progression of chronic hepatitis B
* To observe HBsAg/HBeAg/HBV DNA changes /HBsAg seroconversion
* To determine high rates of Liver Cirrhosis and Hepatocellular Carcinoma
Group 1 : CHB with diabetes Group 2 : CHB with hyperlipemia Group 3 : CHB without metabolic diseases
Study Duration (in months) 24 months
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hyperlipidemia
* HBsAg(+) patients
* TC\>5.17mmol/L（200mg/dl）and（or）TG\>2.3mmol/L（200mg/dl）
No interventions assigned to this group
diabetes
* HBsAg(+) patients
* FPG\>126 mg/dL(7.0 mmol/L)Fasting is defined as no caloric intake for at least 8 h.
No interventions assigned to this group
CHB without metabolic disease
* HBsAg(+) patients
* without diabetes/ obesity/hyperlipidemia
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients on-treatment with NAs
Exclusion Criteria
* History of depression or uncontrolled psychiatric disorders
* Subjects protected by law or not in a position to give consent
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hong Ren
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hong Ren
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
HONG REN, Prof.
Role: PRINCIPAL_INVESTIGATOR
The Second Affiliated Hospital of Chongqing Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The 2nd affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LS2021037
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.